Skip to main content

and
Your search also matched 6 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you.
results, e.g.

No evidence of somatic FGFR3 mutation in various types of carcinoma

Include preview-only content
  1. Article

    Open Access

    Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study

    The anti-VEGF antibody bevacizumab associated with an irinotecan or oxaliplatin-based chemotherapy was proved to be superior to the chemotherapy alone in first or second line treatment of metastatic colorectal...

    Astrid Lièvre, Emmanuelle Samalin, Emmanuel Mitry, Eric Assenat in BMC Cancer (2009)

  2. Article

    Open Access

    Small bowel adenocarcinoma phenoty**, a clinicobiological prognostic study

    Small bowel adenocarcinoma (SBA) is a rare tumour with a poor prognosis. Molecular biology data on SBA carcinogenesis are lacking.

    T Aparicio, M Svrcek, A Zaanan, E Beohou, A Laforest in British Journal of Cancer (2013)

  3. Article

    Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort

    Docetaxel–cisplatin-5-FU chemotherapy is superior to 5-FU-cisplatin in terms of response rate and survival in advanced gastric cancer (AGC), but is more toxic. Oxaliplatin is better tolerated than cisplatin, w...

    Simon Pernot, Emmanuel Mitry, Emmanuelle Samalin, Laetitia Dahan in Gastric Cancer (2014)

  4. Article

    Open Access

    Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection

    A better understanding of the molecular profile of anal squamous cell carcinomas (ASCCs) is necessary to consider new therapeutic approaches, and the identification of prognostic and predictive factors for res...

    Wulfran Cacheux, Etienne Rouleau, Adrien Briaux in British Journal of Cancer (2016)

  5. Article

    Erratum to: Chemoembolization of Neuroendocrine Liver Metastases Using Streptozocin and Tris-acryl Microspheres: Embozar (EMBOsphere + ZAnosaR) Study

    Jean-Pierre Pelage, Audrey Fohlen in CardioVascular and Interventional Radiology (2017)

  6. Article

    Open Access

    Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

    Moxetumomab pasudotox is a recombinant CD22-targeting immunotoxin. Here, we present the long-term follow-up analysis of the pivotal, multicenter, open-label trial (NCT01829711) of moxetumomab pasudotox in pati...

    Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani in Journal of Hematology & Oncology (2021)

  7. Article

    Open Access

    OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients

    Nowadays, evaluation of the efficacy and the duration of treatment, in context of monitoring patients with solid tumors, is based on the RECIST methodology. With these criteria, resistance and/or insensitivity...

    Sébastien Vachenc, Jessica Gobbo, Sarah El Moujarrebe, Isabelle Desmoulins in BMC Cancer (2022)